Adjacent Segment Pathology After Treatment With Cervical Disc Arthroplasty or Anterior Cervical Discectomy and Fusion, Part 1: Radiographic Results at 7-Year Follow-Up
The International Journal of Spine Surgery2020Vol. 14(3), pp. 269–277
Citations Over TimeTop 14% of 2020 papers
Pierce D. Nunley, Eubulus J. Kerr, David A. Cavanaugh, PHILLIP ANDREW UTTER, Peter G. Campbell, Rishi Wadhwa, Kelly Frank, Kyle Marshall, Marcus B. Stone
Abstract
The incidence and risk of RASP is decreased when patients are treated with CDA compared with ACDF. Although the mechanism of CDA that generates this protective effect is not understood, PROs remain unaffected through 7 years despite changes in RASP.
Related Papers
- → Analysis of the three United States Food and Drug Administration investigational device exemption cervical arthroplasty trials(2011)144 cited
- → Two-level cervical disc arthroplasty versus anterior cervical discectomy and fusion: 10-year outcomes of a prospective, randomized investigational device exemption clinical trial(2019)116 cited
- → Prospective study of cervical arthroplasty in 98 patients involved in 1 of 3 separate investigational device exemption studies from a single investigational site with a minimum 2-year follow-up(2010)95 cited
- → Factors affecting reoperations after anterior cervical discectomy and fusion within and outside of a Federal Drug Administration investigational device exemption cervical disc replacement trial(2012)75 cited
- → i-Factor™ Bone Graft versus Autograft in Anterior Cervical Discectomy and Fusion: Two-Year Follow-Up of the Randomized Single-Blinded Food and Drug Administration Investigational Device Exemption Study(2016)2 cited